The action of another PBX1-MEIS1 downstream effector, the previously quoted HIF1α, might represent another mechanism through which PBX1 exert its role in MPN cells; indeed, HIF1α has been recently proposed as a new potential therapeutic target in these diseases (Baumeister et al., 2020). Here, PBX1 is linked to myeloproliferative disorder.